Nikolay Delev

649 citations

24 papers · 409 indexed · 1 hit paper · h-index 9

Co-authors: Lichen Teng Victoria P. Werth Ronald van Vollenhoven Shalabh Singhal Ian M. Catlett Joan T. Merrill Brian J. Sharkey Juan J. Gómez‐Reino
Topics: Psoriasis: Treatment and Pathogenesis (10 papers)Systemic Lupus Erythematosus Research (8 papers)Spondyloarthritis Studies and Treatments (7 papers)
Cited by: Rheumatology Immunology Hematology
Journals: CirculationSHILAP Revista de lepidopterologíaAnnals of the Rheumatic Diseases
Partner nations: United States Australia Netherlands

In The Last Decade

Nikolay Delev

24 papers receiving 401 citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

Deucravacitinib, a Tyrosine Kinase 2 Inhibitor, in Systemic Lupus Erythematosus: A Phase II, Randomized, Double‐Blind, Placebo‐Controlled Trial

2022 139 citations Eric F. Morand, Marilyn C. Pike et al. Arthritis & Rheumatology profile →

Peers

Countries citing papers authored by Nikolay Delev

Since Specialization

Citations

This map shows the geographic impact of Nikolay Delev's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Nikolay Delev with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Nikolay Delev more than expected).

Fields of papers citing papers by Nikolay Delev

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Nikolay Delev. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Nikolay Delev. The network helps show where Nikolay Delev may publish in the future.

Co-authorship network of co-authors of Nikolay Delev

This figure shows the co-authorship network connecting the top 25 collaborators of Nikolay Delev. A scholar is included among the top collaborators of Nikolay Delev based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Nikolay Delev. Nikolay Delev is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work	Indexed citations
1	P105 NEX-T CD19 chimeric antigen receptor (CAR) T-cell therapy CC-97540 (BMS-986353): Preclinical and translational evidence of deep B-cell depletion suitable for study in severe refractory autoimmune diseases 2024 ·SHILAP Revista de lepidopterología ·Georg Schett,Tatyana Feldman,Jeremy S. Abramson,Boyu Hu,(unknown),(unknown),Jerill Thorpe,Ruth A. Salmon,Fan Wu,(unknown),(unknown),David Kugler,(unknown),Nikolay Delev,Amitkumar Mehta	2
2	Effect of iberdomide on cutaneous manifestations in systemic lupus erythematosus: A randomized phase 2 clinical trial 2024 ·Journal of the American Academy of Dermatology ·Victoria P. Werth,Joan T. Merrill,Richard Furie,Thomas E. Dorner,Ronald van Vollenhoven,Peter E. Lipsky,(unknown),(unknown),Peter Schäfer,(unknown),Stan Z. Li,Nikolay Delev	3
3	Plain Language Summary of the PAISLEY study: deucravacitinib as a treatment for people with systemic lupus erythematosus 2024 ·Expert Opinion on Investigational Drugs ·Eric F. Morand,Marilyn C. Pike,Joan T. Merrill,Ronald van Vollenhoven,Victoria P. Werth,(unknown),Nikolay Delev,Vaishali Shah,Brian J. Sharkey,(unknown),Ian M. Catlett,Subhashis Banerjee,Shalabh Singhal	2
4	POS0291 IDENTIFICATION OF SUBSETS OF SLE PATIENTS RESPONSIVE TO IBERDOMIDE BY TRANSCRIPTOMIC ANALYSIS OF BASELINE SAMPLES 2023 ·Annals of the Rheumatic Diseases ·Prathyusha Bachali,Yang Hu,Nikolay Delev,Peter Schäfer,Peter E. Lipsky	2
5	AB0530 DESIGN OF 2 PHASE 3, DOUBLE-BLIND, PLACEBO-CONTROLLED, GLOBAL TRIALS OF DEUCRAVACITINIB, AN ORAL, SELECTIVE, ALLOSTERIC TYROSINE KINASE 2 (TYK2) INHIBITOR, IN PATIENTS WITH ACTIVE SYSTEMIC LUPUS ERYTHEMATOSUS 2023 ·Annals of the Rheumatic Diseases ·Cristina Arriens,Anca Askanase,Richard Furie,Eric F. Morand,Ronald van Vollenhoven,(unknown),M. K. Davey,Nikolay Delev,(unknown),(unknown),(unknown),(unknown)	1
6	Efficacy and safety of deucravacitinib, an oral, selective, allosteric TYK2 inhibitor, in patients with active systemic lupus erythematosus: Results from a phase 2, randomized, double-blind, placebo-controlled study 2023 ·SKIN The Journal of Cutaneous Medicine ·Victoria P. Werth,Marilyn C. Pike,Joan T. Merrill,Eric F. Morand,Ronald van Vollenhoven,(unknown),Nikolay Delev,Vaishali Shah,Brian J. Sharkey,(unknown),Ian M. Catlett,Subhashis Banerjee,Shalabh Singhal	1
7	Deucravacitinib, a Tyrosine Kinase 2 Inhibitor, in Systemic Lupus Erythematosus: A Phase II, Randomized, Double‐Blind, Placebo‐Controlled Trialbreakdown → 2022 ·Arthritis & Rheumatology ·Eric F. Morand,Marilyn C. Pike,Joan T. Merrill,Ronald van Vollenhoven,Victoria P. Werth,(unknown),Nikolay Delev,(unknown),Brian J. Sharkey,(unknown),Ian M. Catlett,Subhashis Banerjee,Shalabh Singhal	139
8	PO.6.132 A phase 2b study of afimetoran (BMS-986256) in patients with active systemic lupus erythematosus (SLE): optimization of a lupus clinical trial design 2022 ·SHILAP Revista de lepidopterología ·(unknown),JT Merrill,(unknown),Nikolay Delev,Sreeparna Banerjee,Dennis M. Grasela,Melanie Harrison,Yun Shen,(unknown),Steven Greenberg,(unknown)	2
9	LB0004 EFFICACY AND SAFETY OF DEUCRAVACITINIB, AN ORAL, SELECTIVE, ALLOSTERIC TYK2 INHIBITOR, IN PATIENTS WITH ACTIVE SYSTEMIC LUPUS ERYTHEMATOSUS: A PHASE 2, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY 2022 ·Annals of the Rheumatic Diseases ·(unknown),(unknown),JT Merrill,Ronald van Vollenhoven,(unknown),(unknown),Nikolay Delev,(unknown),Brian J. Sharkey,(unknown),Ian M. Catlett,(unknown),Shalabh Singhal	16
10	POS1048 SAFETY AND EFFICACY OF DEUCRAVACITINIB, AN ORAL, SELECTIVE TYROSINE KINASE 2 INHIBITOR, IN PATIENTS WITH PSORIATIC ARTHRITIS: 52-WEEK RESULTS FROM A RANDOMISED PHASE 2 TRIAL 2022 ·Annals of the Rheumatic Diseases ·(unknown),Atul Deodhar,D. van der Heijde,(unknown),(unknown),Jeffrey Neal,(unknown),Thomas Lehman,Nikolay Delev,(unknown),Miroslawa Nowak,(unknown)	5
11	OP0132 EFFECT OF IBERDOMIDE ON CUTANEOUS MANIFESTATIONS IN SYSTEMIC LUPUS ERYTHEMATOSUS: RESULTS OF A 24-WEEK, PLACEBO-CONTROLLED, PHASE 2 STUDY 2021 ·Annals of the Rheumatic Diseases ·Victoria P. Werth,Joan T. Merrill,Richard Furie,Thomas Dörner,Ronald van Vollenhoven,Peter E. Lipsky,(unknown),(unknown),Peter Schäfer,Martin Stern,(unknown),Shijie Tang,Nikolay Delev	7
12	Long‐Term Safety and Tolerability of Apremilast Versus Placebo in Psoriatic Arthritis: A Pooled Safety Analysis of Three Phase III, Randomized, Controlled Trials 2020 ·ACR Open Rheumatology ·Philip J. Mease,Dafna D. Gladman,Juan J. Gómez‐Reino,Stephen Hall,Arthur Kavanaugh,Éric Lespessailles,Georg Schett,Maria Paris,Nikolay Delev,Lichen Teng,J. Wollenhaupt	16
13	Long-term experience with apremilast in patients with psoriatic arthritis: 5-year results from a PALACE 1–3 pooled analysis 2019 ·Arthritis Research & Therapy ·Arthur Kavanaugh,Dafna D. Gladman,Christopher J Edwards,Georg Schett,B. Guérette,Nikolay Delev,Lichen Teng,Maria Paris,Philip J. Mease	57
14	Early and sustained efficacy with apremilast monotherapy in biological-naïve patients with psoriatic arthritis: a phase IIIB, randomised controlled trial (ACTIVE) 2018 ·Annals of the Rheumatic Diseases ·Peter Nash,Kamal Ohson,Jessica A. Walsh,Nikolay Delev,Dianne Nguyen,Lichen Teng,Juan J. Gómez‐Reino,Jacob Aelion	66
15	Therapeutic benefit of apremilast on enthesitis and dactylitis in patients with psoriatic arthritis: a pooled analysis of the PALACE 1–3 studies 2018 ·RMD Open ·Dafna D. Gladman,Arthur Kavanaugh,Juan J. Gómez‐Reino,J. Wollenhaupt,Maurizio Cutolo,Georg Schett,Éric Lespessailles,B. Guérette,Nikolay Delev,Lichen Teng,Christopher J Edwards,C. Birbara,Philip J. Mease	27
16	FRI0487 Apremilast is associated with long-term (4-YEAR) DAS-28 (CRP) remission and improvements in skin disease: results from a phase iii study in dmard/biologic-experienced patients with active psoriatic arthritis 2017 ·Annals of the Rheumatic Diseases ·(unknown),Francisco J. Blanco,Jeffrey Crowley,M. McIlraith,Maria Paris,Nikolay Delev,Lichen Teng,(unknown)	4
17	OP0219 Early onset of efficacy with apremilast monotherapy in biologic-naÏve patients with active psoriatic arthritis: a phase 3b, randomized, controlled trial 2017 ·Annals of the Rheumatic Diseases ·Peter Nash,Kamal Ohson,Jessica A. Walsh,Nikolay Delev,Duc Thanh Nguyen,Lichen Teng,(unknown),(unknown)	3
18	SAT0255 A randomized, placebo-controlled, double-blind, ascending-dose, safety study of CC-220 in subjects with systemic lupus erythematosus 2017 ·Annals of the Rheumatic Diseases ·V. Werth,Richard Furie,(unknown),(unknown),Ada Azaryan,(unknown),Nikolay Delev,(unknown),Douglas R. Hough	5
19	CT-07 A phase 2, randomised, placebo-controlled, double-blind, ascending dose study to evaluate efficacy, safety, and tolerability, pharmacokinetics, pharmacodynamics and pharmacogenetics of CC-220 in subjects with systemic lupus erythematosus 2016 ·Clinical Trials ·Victoria P. Werth,Douglas R. Hough,(unknown),(unknown),Peter Schäfer,Nikolay Delev,(unknown)	1
20	[Tumors of the urachus]. 1965 ·PubMed ·Nikolay Delev	7

About Nikolay Delev

Nikolay Delev is a scholar working on Rheumatology, Immunology and Oncology, having authored 24 papers that have together received 409 indexed citations. Recurring topics across this work include Psoriasis: Treatment and Pathogenesis (10 papers), Systemic Lupus Erythematosus Research (8 papers) and Spondyloarthritis Studies and Treatments (7 papers). The work is most often cited by research in Rheumatology (295 citations), Immunology (244 citations) and Hematology (101 citations). Nikolay Delev has collaborated with scholars based in United States, Australia and Netherlands. Frequent co-authors include Lichen Teng, Victoria P. Werth, Ronald van Vollenhoven, Shalabh Singhal, Ian M. Catlett, Joan T. Merrill, Brian J. Sharkey, Juan J. Gómez‐Reino, Eric F. Morand and Marilyn C. Pike. Their work appears in journals such as Circulation, SHILAP Revista de lepidopterología and Annals of the Rheumatic Diseases.

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact